2024-10-26 10:13:16 :
Jubilant Pharmova Second Quarter Results Live: Jubilant Pharmova reported second quarter results on October 25, 2024, showing significant growth in profitability. The company’s revenue increased by 4.28% year-on-year, and its profit increased by 64.48% year-on-year. Although the year-on-year performance was good, it declined slightly compared with the previous quarter, with revenue growing only 1.19% and profit falling sharply by 78.68%.
In terms of expenses, selling, general and administrative expenses increased by 2.06% month-on-month and 6.11% year-on-year. The increase in expenses may lead to a decrease in operating income, which fell 66.98% from the previous quarter despite a year-on-year increase of 26.58%.
Second quarter earnings per share (EPS) reported at $7.09, an impressive 80.04% increase compared to the same period last year. Investors may find this number encouraging, as it indicates steady growth in earnings per share.
Jubilant Pharmova faced a slight decline over the past week, returning -5.57%. However, the company has shown significant recovery over the longer term, returning 63.48% over the past six months and an impressive 103.14% year-to-date. This performance brought the market capitalization to $17,551.15 Cr, 52-week high $1247.15 and lowest price $318.75.
Looking ahead, analyst sentiment remains positive. Of the three analysts covering the company as of October 26, 2024, one has a Buy rating and two have a Strong Buy rating. The consensus recommendation was a “Strong Buy,” indicating confidence in the company’s future performance.
Thriving pharmaceutical company finances
period | Q2 | Q1 | month-on-month growth | Q2 | year-on-year growth |
---|---|---|---|---|---|
total revenue | 1752.3 | 1731.7 | +1.19% | 1680.3 | +4.28% |
Total Selling/General/Administrative Expenses | 564.3 | 552.9 | +2.06% | 531.8 | +6.11% |
Depreciation/Amortization | 91.4 | 90.7 | +0.77% | 96.6 | -5.38% |
total operating expenses | 1568.5 | Chapter 1175 | +33.49% | 1535.1 | +2.18% |
operating income | 183.8 | 556.7 | -66.98% | 145.2 | +26.58% |
net income before tax | 144.4 | 499.7 | -71.1% | 98 | +47.35% |
net income | 102.8 | 482.1 | -78.68% | 62.5 | +64.48% |
Diluted normalized earnings per share | 7.09 | 6.34 | +11.92% | 3.94 | +80.04% |
Follow us On Social Media   Twitter/X